Evaluating potential changes in MHRA guidelines for Clozapine Monitoring
Clozapine is the treatment of choice in refractory schizophrenia, but it remains an underused medication. In the US, FDA changes were made to clozapine monitoring requirements to improve access to treatment. This project aims to examine the potential impact these changes would have in the UK if implemented.